MA40481A - Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante - Google Patents
Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutanteInfo
- Publication number
- MA40481A MA40481A MA040481A MA40481A MA40481A MA 40481 A MA40481 A MA 40481A MA 040481 A MA040481 A MA 040481A MA 40481 A MA40481 A MA 40481A MA 40481 A MA40481 A MA 40481A
- Authority
- MA
- Morocco
- Prior art keywords
- pyridin
- isocitrate dehydrogenase
- dehydrogenase inhibitors
- mutant isocitrate
- quinolinone derivatives
- Prior art date
Links
- 102000012011 Isocitrate Dehydrogenase Human genes 0.000 title abstract 2
- 108010075869 Isocitrate Dehydrogenase Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000003538 neomorphic effect Effects 0.000 abstract 1
- 229940121649 protein inhibitor Drugs 0.000 abstract 1
- 239000012268 protein inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462053006P | 2014-09-19 | 2014-09-19 | |
| US201562128089P | 2015-03-04 | 2015-03-04 | |
| US201562150812P | 2015-04-21 | 2015-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40481A true MA40481A (fr) | 2017-07-26 |
Family
ID=54291606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040481A MA40481A (fr) | 2014-09-19 | 2015-09-18 | Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante |
| MA053352A MA53352A (fr) | 2014-09-19 | 2015-09-18 | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053352A MA53352A (fr) | 2014-09-19 | 2015-09-18 | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase |
Country Status (37)
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108524505A (zh) | 2009-03-13 | 2018-09-14 | 安吉奥斯医药品有限公司 | 用于细胞增殖相关病症的方法和组合物 |
| ES2594402T3 (es) | 2009-10-21 | 2016-12-20 | Agios Pharmaceuticals, Inc. | Métodos y composiciones para trastornos relacionados con la proliferación celular |
| SMT202400446T1 (it) | 2014-02-06 | 2024-11-15 | Nxera Pharma Uk Ltd | Composti aza biciclici come agonisti del recettore muscarinico |
| CA2961807A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| JP6648116B2 (ja) * | 2014-09-19 | 2020-02-14 | フォーマ セラピューティクス，インコーポレイテッド | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物 |
| TN2017000092A1 (en) | 2014-09-19 | 2018-07-04 | Bayer Pharma AG | Benzyl substituted indazoles as bub1 inhibitors. |
| LT3194376T (lt) * | 2014-09-19 | 2019-02-25 | Forma Therapeutics, Inc. | Piridin-2(1h)-ono chinolinono dariniai, kaip mutantinės izocitratdehidrogenazės inhibitoriai |
| MX373789B (es) | 2014-09-19 | 2020-03-23 | Forma Therapeutics Inc | Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh). |
| ES2905564T3 (es) | 2014-12-22 | 2022-04-11 | Us Health | Inhibidores mutantes de IDH1 útiles para tratar el cáncer |
| US10407419B2 (en) | 2015-04-21 | 2019-09-10 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| WO2016171755A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| SI3619196T1 (sl) | 2017-05-04 | 2022-10-28 | Bayer Cropscience Aktiengesellschaft | 2-((2-(feniloksimetil)piridin-5-il)oksi)-etanaminski derivati in sorodne spojine kot sredstva za zatiranje škodljivcev, npr. za zaščito rastlin |
| US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
| WO2019222551A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
| SI3720442T1 (sl) | 2018-05-16 | 2023-06-30 | Forma Therapeutics, Inc. | Zaviranje mutantnega IDF-1 |
| US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
| WO2020232381A1 (en) | 2019-05-16 | 2020-11-19 | Forma Therapeutics, Inc. | INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1) |
| US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
| WO2019222553A1 (en) | 2018-05-16 | 2019-11-21 | Forma Therapeutics, Inc. | Inhibiting mutant idh-1 |
| TW202104207A (zh) * | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
| US11566013B1 (en) * | 2019-11-20 | 2023-01-31 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1) |
| CN112341389B (zh) * | 2020-10-27 | 2022-07-29 | 浙江工业大学 | 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用 |
| CN112321571B (zh) * | 2020-10-27 | 2022-06-03 | 浙江工业大学 | 2-呋喃-喹啉-4-甲酰胺类化合物及其应用 |
| CN115850240B (zh) * | 2022-12-28 | 2023-09-19 | 北京康立生医药技术开发有限公司 | 一种治疗急性髓系白血病药物奥卢他西尼的合成方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99731A0 (en) | 1990-10-18 | 1992-08-18 | Merck & Co Inc | Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| US20030105124A1 (en) | 2000-04-27 | 2003-06-05 | Susan Beth Sobolov-Jaynes | Substituted benzolactam compounds |
| AU2003243497A1 (en) | 2002-06-12 | 2003-12-31 | Millennium Pharmaceuticals, Inc. | Antagonists of melanin concentrating hormone receptor |
| JPWO2004043936A1 (ja) | 2002-11-14 | 2006-03-09 | 協和醗酵工業株式会社 | Ｐｌｋ阻害剤 |
| RU2284325C2 (ru) * | 2003-12-17 | 2006-09-27 | Общество С Ограниченной Ответственностью "Асинэкс Медхим" | Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе |
| WO2005095382A1 (ja) | 2004-03-30 | 2005-10-13 | Kyowa Hakko Kogyo Co., Ltd. | 抗腫瘍剤 |
| WO2006054912A1 (fr) | 2004-11-18 | 2006-05-26 | Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' | Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base |
| TW200803855A (en) | 2006-02-24 | 2008-01-16 | Kalypsys Inc | Quinolones useful as inducible nitric oxide synthase inhibitors |
| WO2008010964A1 (en) * | 2006-07-17 | 2008-01-24 | Merck & Co., Inc. | 1-hydroxy naphthyridine compounds as anti-hiv agents |
| JP2010043004A (ja) | 2006-12-06 | 2010-02-25 | Dainippon Sumitomo Pharma Co Ltd | 新規２環性複素環化合物 |
| CN101679321B (zh) | 2007-04-30 | 2012-10-03 | 普罗米蒂克生物科学公司 | 三嗪衍生物、含所述衍生物的组合物以及所述衍生物在制备用于治疗癌症和自身免疫性疾病药物中的应用 |
| CN102573485B (zh) | 2009-06-08 | 2014-11-26 | 加利福尼亚资本权益有限责任公司 | 三嗪衍生物及其治疗应用 |
| EP2509600B1 (en) * | 2009-12-09 | 2017-08-02 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation |
| WO2012006104A2 (en) | 2010-06-28 | 2012-01-12 | Academia Sinica, Taiwan | Compounds and methods for treating tuberculosis infection |
| CN102558049B (zh) * | 2010-12-17 | 2015-02-04 | 中国科学院上海药物研究所 | 一类双香豆素类化合物及其制备方法和用途 |
| US20120184548A1 (en) | 2011-01-19 | 2012-07-19 | Romyr Dominique | Carboxylic acid aryl amides |
| US20120184562A1 (en) | 2011-01-19 | 2012-07-19 | Kin-Chun Luk | 1,6- and 1,8-naphthyridines |
| US9464065B2 (en) | 2011-03-24 | 2016-10-11 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| CN103814020B (zh) * | 2011-06-17 | 2017-07-14 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| AP3907A (en) | 2011-09-27 | 2016-11-23 | Novartis Ag | 3-Pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
| US9353121B2 (en) | 2011-12-21 | 2016-05-31 | The Regents Of The University Of Colorado, A Body Corporate | Anti-cancer compounds targeting Ral GTPases and methods of using the same |
| SI2800743T1 (en) * | 2012-01-06 | 2018-08-31 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and methods for their use |
| EP2970242B1 (en) * | 2013-03-14 | 2017-09-06 | Novartis AG | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| WO2015003146A1 (en) | 2013-07-03 | 2015-01-08 | Georgetown University | Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
| MX2016010474A (es) | 2014-02-11 | 2016-10-31 | Bayer Pharma AG | Benzimidazol-2-aminas como inhibidores de midh1. |
| MX373789B (es) | 2014-09-19 | 2020-03-23 | Forma Therapeutics Inc | Derivados de piridinil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh). |
| CA2961807A1 (en) | 2014-09-19 | 2016-03-24 | Forma Therapeutics, Inc. | Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| JP6648116B2 (ja) * | 2014-09-19 | 2020-02-14 | フォーマ セラピューティクス，インコーポレイテッド | 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物 |
| LT3194376T (lt) | 2014-09-19 | 2019-02-25 | Forma Therapeutics, Inc. | Piridin-2(1h)-ono chinolinono dariniai, kaip mutantinės izocitratdehidrogenazės inhibitoriai |
| ES2905564T3 (es) | 2014-12-22 | 2022-04-11 | Us Health | Inhibidores mutantes de IDH1 útiles para tratar el cáncer |
| GB2533925A (en) | 2014-12-31 | 2016-07-13 | Univ Bath | Antimicrobial compounds, compositions and methods |
| US10407419B2 (en) | 2015-04-21 | 2019-09-10 | Forma Therapeutics, Inc. | Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors |
| WO2016171755A1 (en) | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| ES2764523T3 (es) | 2015-07-27 | 2020-06-03 | Lilly Co Eli | Compuestos de 7-feniletilamino-4H-pirimido[4,5-D][1,3]oxazin-2-ona y su uso como inhibidores de IDH1 mutantes |
| JP6930991B2 (ja) | 2016-02-26 | 2021-09-01 | セルジーン コーポレイション | 血液学的悪性腫瘍及び固形腫瘍の治療のためのｉｄｈ２阻害剤 |
| ES2814290T3 (es) | 2016-06-06 | 2021-03-26 | Lilly Co Eli | Inhibidores de IDH1 mutante |
| ES2880347T3 (es) | 2016-06-22 | 2021-11-24 | Us Health | Derivados de tiazol útiles como inhibidores de IDH1 mutante para el tratamiento del cáncer |
| NZ754115A (en) | 2016-12-16 | 2021-07-30 | Lilly Co Eli | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors |
-
2015
- 2015-09-18 LT LTEP15778433.1T patent/LT3194376T/lt unknown
- 2015-09-18 BR BR112017005238-5A patent/BR112017005238B1/pt active IP Right Grant
- 2015-09-18 CN CN201580050441.5A patent/CN107001328B/zh active Active
- 2015-09-18 AU AU2015317329A patent/AU2015317329B2/en active Active
- 2015-09-18 MA MA040481A patent/MA40481A/fr unknown
- 2015-09-18 ES ES18198969T patent/ES2790640T3/es active Active
- 2015-09-18 PT PT15778433T patent/PT3194376T/pt unknown
- 2015-09-18 FI FIEP20157755.8T patent/FI3733662T3/fi active
- 2015-09-18 IL IL292608A patent/IL292608B2/en unknown
- 2015-09-18 PH PH1/2017/500517A patent/PH12017500517B1/en unknown
- 2015-09-18 PE PE2017000471A patent/PE20171056A1/es unknown
- 2015-09-18 PL PL15778433T patent/PL3194376T3/pl unknown
- 2015-09-18 PL PL18198969T patent/PL3447050T3/pl unknown
- 2015-09-18 SM SM20190018T patent/SMT201900018T1/it unknown
- 2015-09-18 TW TW104131044A patent/TWI686390B/zh active
- 2015-09-18 MY MYPI2017700895A patent/MY176250A/en unknown
- 2015-09-18 HU HUE15778433A patent/HUE041460T2/hu unknown
- 2015-09-18 LT LTEP18198969.0T patent/LT3447050T/lt unknown
- 2015-09-18 SM SM20200212T patent/SMT202000212T1/it unknown
- 2015-09-18 EP EP20157755.8A patent/EP3733662B1/en active Active
- 2015-09-18 CN CN202010391529.6A patent/CN111909130B/zh active Active
- 2015-09-18 RS RS20181586A patent/RS58184B1/sr unknown
- 2015-09-18 US US14/858,167 patent/US9834539B2/en active Active
- 2015-09-18 DK DK15778433.1T patent/DK3194376T3/en active
- 2015-09-18 PL PL20157755.8T patent/PL3733662T3/pl unknown
- 2015-09-18 ES ES20157755T patent/ES2953347T3/es active Active
- 2015-09-18 MA MA053352A patent/MA53352A/fr unknown
- 2015-09-18 MX MX2019013203A patent/MX385512B/es unknown
- 2015-09-18 ME MEP-2020-78A patent/ME03776B/me unknown
- 2015-09-18 SI SI201531117T patent/SI3447050T1/sl unknown
- 2015-09-18 EP EP15778433.1A patent/EP3194376B1/en active Active
- 2015-09-18 SI SI201530537T patent/SI3194376T1/sl unknown
- 2015-09-18 JP JP2017515059A patent/JP6648115B2/ja active Active
- 2015-09-18 WO PCT/US2015/051055 patent/WO2016044789A1/en not_active Ceased
- 2015-09-18 KR KR1020177010585A patent/KR102209667B1/ko active Active
- 2015-09-18 SG SG11201702194SA patent/SG11201702194SA/en unknown
- 2015-09-18 RS RS20200418A patent/RS60140B1/sr unknown
- 2015-09-18 PT PT201577558T patent/PT3733662T/pt unknown
- 2015-09-18 CN CN202311265288.0A patent/CN117695280A/zh active Pending
- 2015-09-18 HU HUE20157755A patent/HUE062424T2/hu unknown
- 2015-09-18 MX MX2017003404A patent/MX2017003404A/es active IP Right Grant
- 2015-09-18 EP EP18198969.0A patent/EP3447050B1/en active Active
- 2015-09-18 EP EP23176702.1A patent/EP4257131A3/en active Pending
- 2015-09-18 ES ES15778433T patent/ES2704897T3/es active Active
- 2015-09-18 DK DK18198969.0T patent/DK3447050T3/da active
- 2015-09-18 NZ NZ73037315A patent/NZ730373A/en unknown
- 2015-09-18 PT PT181989690T patent/PT3447050T/pt unknown
- 2015-09-18 EA EA201790657A patent/EA034336B1/ru unknown
- 2015-09-18 CA CA2961817A patent/CA2961817C/en active Active
- 2015-09-18 MY MYPI2020001463A patent/MY197533A/en unknown
-
2017
- 2017-03-07 US US15/452,256 patent/US20170174658A1/en not_active Abandoned
- 2017-03-14 IL IL251163A patent/IL251163B/en active IP Right Grant
- 2017-03-17 CL CL2017000658A patent/CL2017000658A1/es unknown
- 2017-03-19 SA SA517381129A patent/SA517381129B1/ar unknown
- 2017-03-27 ZA ZA2017/02127A patent/ZA201702127B/en unknown
- 2017-04-03 CO CONC2017/0003241A patent/CO2017003241A2/es unknown
- 2017-04-13 EC ECIEPI201722933A patent/ECSP17022933A/es unknown
-
2018
- 2018-04-27 US US15/964,844 patent/US10414752B2/en active Active
-
2019
- 2019-01-21 CY CY20191100075T patent/CY1121149T1/el unknown
- 2019-03-01 US US16/290,240 patent/US10550098B2/en active Active
- 2019-04-17 ZA ZA2019/02446A patent/ZA201902446B/en unknown
- 2019-12-12 US US16/712,951 patent/US10889567B2/en active Active
- 2019-12-16 AU AU2019283765A patent/AU2019283765B2/en active Active
-
2020
- 2020-04-24 HR HRP20200666TT patent/HRP20200666T1/hr unknown
- 2020-05-04 CY CY20201100407T patent/CY1122865T1/el unknown
- 2020-11-23 US US17/101,018 patent/US11498913B2/en active Active
-
2021
- 2021-04-18 IL IL282363A patent/IL282363B/en unknown
- 2021-08-10 AU AU2021215141A patent/AU2021215141B2/en active Active
-
2022
- 2022-11-09 US US17/984,069 patent/US20230125739A1/en not_active Abandoned
-
2023
- 2023-04-14 ZA ZA2023/04409A patent/ZA202304409B/en unknown
- 2023-11-09 US US18/506,060 patent/US12275715B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40481A (fr) | Dérivés de pyridin-2-(1h)-one-quinolinone à titre d'inhibiteurs d'isocitrate déshydrogénase mutante | |
| PH12019502264A1 (en) | Fused imidazo-piperidine jak inhibitors compound | |
| MA39898B1 (fr) | Composés 4-amino-imidazoquinoline | |
| MX2018015625A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| EA202092636A1 (ru) | Способ синтеза 2-гидрокси-6-((2-(1-изопропил-1h-пиразол-5-ил)пиридин-3-ил)метокси)бензальдегида | |
| EA200601364A1 (ru) | Производные хинолина и их применение в качестве ингибиторов микобактерий | |
| EA201792047A1 (ru) | Новые соединения | |
| EA201690199A1 (ru) | Лекарственное средство для лечения неалкогольной жировой болезни печени | |
| MX391812B (es) | Agonista fxr derivado de esteroides. | |
| EA201390711A1 (ru) | Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения | |
| MA39172A1 (fr) | Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines | |
| EA201491012A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
| EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
| MA35643B1 (fr) | Inhibiteur de cetp d'oxazolidinone bicyclique condensée | |
| EA201691803A1 (ru) | Ингибиторы калликреина плазмы человека | |
| MA41238B1 (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
| PH12017500841B1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| EA201391288A1 (ru) | Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз | |
| MA40993A (fr) | Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139 | |
| EA201791259A1 (ru) | Производные пиперидина в качестве ингибиторов hdac1/2 | |
| MA39171A1 (fr) | Dérivés d'hydroxy formamide et leur utilisation | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| CL2013003068A1 (es) | Compuestos derivados de 2-(etinil-piridin-2-il)-pirazolidin-3-ona, 2-(etinil-pirimidin-2-il)-pirazolidin-3-ona o 2-(etinil-piridazin-3-il)-pirazolidin-3-ona; moduladores alostericos positivos de mglur5; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar la esquizofrenia o enfermedades cognitivas. | |
| MA38250B1 (fr) | Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie |